(Q38154911)

29 August 2017

Clinical validity of cytochrome P450 metabolism and serotonin gene variants in psychiatric pharmacotherapy (English)

1 reference

29 August 2017

0 references

0 references

C Anthony Altar

1

1 reference

29 August 2017

John Hornberger

2

1 reference

29 August 2017

Ashwini Shewade

3

1 reference

29 August 2017

Victor Cruz

4

1 reference

29 August 2017

Jill Garrison

5

1 reference

29 August 2017

David Mrazek

6

1 reference

29 August 2017

language of work or name

1 reference

1 October 2013

1 reference

International Review of Psychiatry

29 August 2017

1 reference

29 August 2017

25

1 reference

29 August 2017

5

1 reference

29 August 2017

509-533

1 reference

Assessing the economic costs of serious mental illness.

29 August 2017

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Pharmacogenetics studies in STAR*D: strengths, limitations, and results

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Pharmacogenomics of psychiatric disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Lack of association between the T-->C 267 serotonin 5-HT6 receptor gene (HTR6) polymorphism and prediction of response to clozapine in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Polymorphic variations in GSTM1, GSTT1, PgP, CYP2D6, CYP3A5, and dopamine D2 and D3 receptors and their association with tardive dyskinesia in severe mental illness

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Evidence for a combined genetic effect of the 5-HT(1A) receptor and serotonin transporter genes in the clinical outcome of major depressive patients treated with citalopram

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Antidepressant response and the serotonin transporter gene-linked polymorphic region

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

SLC6A4 variation and citalopram response

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

The impact of CYP allelic variation on antidepressant metabolism: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Pharmacogenetics of antidepressant response

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Sequence variations of ABCB1, SLC6A2, SLC6A3, SLC6A4, CREB1, CRHR1 and NTRK2: association with major depression and antidepressant response in Mexican-Americans

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Association between common variants near the melanocortin 4 receptor gene and severe antipsychotic drug-induced weight gain

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Pharmacogenomics: the promise of personalized medicine for CNS disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Drug-metabolizing enzyme genotypes and aggressive behavior treatment response in hospitalized pediatric psychiatric patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

The promise and reality of pharmacogenetics in psychiatry.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Recommendations from the EGAPP Working Group: testing for cytochrome P450 polymorphisms in adults with nonpsychotic depression treated with selective serotonin reuptake inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects prediction

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Influence of the CYP2D6*4 polymorphism on dose, switching and discontinuation of antidepressants

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Relevance of CYP2D6 -1584C>G polymorphism for thioridazine:mesoridazine plasma concentration ratio in psychiatric patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Paroxetine: population pharmacokinetic analysis in late-life depression using sparse concentration sampling

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Population pharmacokinetic analysis of mirtazapine

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

ABCB1 polymorphisms influence steady-state plasma levels of 9-hydroxyrisperidone and risperidone active moiety.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

The CYP2D6 polymorphism in relation to the metabolism of amitriptyline and nortriptyline in the Faroese population

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Impact of CYP2D6 genotype on steady-state serum concentrations of risperidone and 9-hydroxyrisperidone in patients using long-acting injectable risperidone

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Serum concentrations of venlafaxine and its metabolites O-desmethylvenlafaxine and N-desmethylvenlafaxine in heterozygous carriers of the CYP2D6*3, *4 or *5 allele

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Semi-quantitative CYP2D6 gene doses in relation to metabolic ratios of psychotropics

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

CYP2C19 genotype predicts steady state escitalopram concentration in GENDEP.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

The role of CYP2D6 and ABCB1 pharmacogenetics in drug-naïve patients with first-episode schizophrenia treated with risperidone

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Effects of CYP2D6 and CYP3A5 genotypes on the plasma concentrations of risperidone and 9-hydroxyrisperidone in Korean schizophrenic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Population pharmacokinetic modelling of aripiprazole and its active metabolite, dehydroaripiprazole, in psychiatric patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Steady-state concentrations of mirtazapine, N-desmethylmirtazapine, 8-hydroxymirtazapine and their enantiomers in relation to cytochrome P450 2D6 genotype, age and smoking behaviour.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

QTc interval, CYP2D6 and CYP2C9 genotypes and risperidone plasma concentrations.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Cytochrome P450 2D6 genotype variation and venlafaxine dosage

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Effects of dosage and CYP2D6-mutated allele on plasma concentration of paroxetine

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Influence of CYP2C9, 2C19 and 2D6 genetic polymorphisms on the steady-state plasma concentrations of the enantiomers of fluoxetine and norfluoxetine

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Allele-specific change of concentration and functional gene dose for the prediction of steady-state serum concentrations of amitriptyline and nortriptyline in CYP2C19 and CYP2D6 extensive and intermediate metabolizers

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Effect of the cytochrome P450 2D6*10 allele on risperidone metabolism in Japanese psychiatric patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Metabolic ratios of psychotropics as indication of cytochrome P450 2D6/2C19 genotype

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Dose-dependent effect of the CYP2D6 genotype on the steady-state fluvoxamine concentration

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

CYP2D6 genotype and venlafaxine-XR concentrations in depressed elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Effects of the CYP2D6*10 alleles and co-medication with CYP2D6-dependent drugs on risperidone metabolism in patients with schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Effects of various factors on steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone: lack of impact of MDR-1 genotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Haloperidol half-life after chronic dosing

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Effects of cigarette smoking and cytochrome P450 2D6 genotype on fluvoxamine concentration in plasma of Japanese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

The relationship between the response of clinical symptoms and plasma olanzapine concentration, based on pharmacogenetics: Juntendo University Schizophrenia Projects (JUSP).

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Risperidone plasma levels, clinical response and side-effects

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Gene polymorphism influencing treatment response in psychotic patients in a naturalistic setting

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

ABCB1 and cytochrome P450 polymorphisms: clinical pharmacogenetics of clozapine.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Effect of smoking and CYP2D6 polymorphisms on the extent of fluvoxamine-alprazolam interaction in patients with psychosomatic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Consistency of drug-drug and gene-drug interaction information in US FDA-approved drug labels

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

The influence of the CYP2D6 polymorphism on psychopathological and extrapyramidal symptoms in the patients on long-term antipsychotic treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

CYP2D6 genotype: impact on adverse effects and nonresponse during treatment with antidepressants-a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Genetic polymorphisms of cytochrome P450 enzymes influence metabolism of the antidepressant escitalopram and treatment response.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Prediction of response to risperidone treatment with respect to plasma concencentrations of risperidone, catecholamine metabolites, and polymorphism of cytochrome P450 2D6.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Naturalistic pharmacogenetic study of treatment resistance to typical neuroleptics in European-Brazilian schizophrenics

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Pharmacokinetic genes do not influence response or tolerance to citalopram in the STAR*D sample

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Correlates of response to Olanzapine in a North Indian Schizophrenia sample.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Links among paroxetine-induced sexual dysfunctions, gender, and CYP2D6 activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

CYP2C19 variation and citalopram response

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Will a new genotyping test help the clinician predict response to antidepressant drugs?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

The AmpliChip® CYP450 test and response to treatment in schizophrenia and obsessive compulsive disorder: a pilot study and focus on cases with abnormal CYP2D6 drug metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

CYP2D6 genotype predicts antipsychotic side effects in schizophrenia inpatients: a retrospective matched case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Cytochrome P-450 2D6*10 C188T polymorphism is associated with antipsychotic-induced persistent tardive dyskinesia in Chinese schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Polymorphisms in the 5-hydroxytryptamine 2A receptor and CytochromeP4502D6 genes synergistically predict fluvoxamine-induced side effects in japanese depressed patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Amitriptyline or not, that is the question: pharmacogenetic testing of CYP2D6 and CYP2C19 identifies patients with low or high risk for side effects in amitriptyline therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

No evidence of increased adverse drug reactions in cytochrome P450 CYP2D6 poor metabolizers treated with fluoxetine or nortriptyline

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Effect of age, weight, and CYP2C19 genotype on escitalopram exposure

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Serum concentrations of sertraline and N-desmethyl sertraline in relation to CYP2C19 genotype in psychiatric patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Impact of the ultrarapid CYP2C19*17 allele on serum concentration of escitalopram in psychiatric patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Phenotype-genotype relationship and clinical effects of citalopram in Chinese patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Effect of CYP2D6 and CYP2C9 genotypes on fluoxetine and norfluoxetine plasma concentrations during steady-state conditions.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Relationship between haloperidol plasma concentration, debrisoquine metabolic ratio, CYP2D6 and CYP2C9 genotypes in psychiatric patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Genetic association analysis of functional polymorphisms in the cytochrome P450 1A2 (CYP1A2) gene with tardive dyskinesia in Japanese patients with schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Pharmacogenetics and olanzapine treatment: CYP1A2*1F and serotonergic polymorphisms influence therapeutic outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Carriers of the UGT1A4 142T>G gene variant are predisposed to reduced olanzapine exposure--an impact similar to male gender or smoking in schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

The cytochrome P450 CYP1A2 genetic polymorphisms *1F and *1D do not affect clozapine clearance in a group of schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

CYP1A2 genetic polymorphisms are associated with treatment response to the antidepressant paroxetine.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Genetic contribution to variable human CYP3A-mediated metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Pharmacogenomics as molecular autopsy for forensic toxicology: genotyping cytochrome P450 3A4*1B and 3A5*3 for 25 fentanyl cases

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

CYP3A4 gene polymorphisms influence testosterone 6beta-hydroxylation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Association of carbamazepine major metabolism and transport pathway gene polymorphisms and pharmacokinetics in patients with epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Impact of CYP3A4*1G polymorphism on metabolism of fentanyl in Chinese patients undergoing lower abdominal surgery.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Effect of CYP3A4*1G on the fentanyl consumption for intravenous patient-controlled analgesia after total abdominal hysterectomy in Chinese Han population.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

CYP3A4*16 and CYP3A4*18 alleles found in East Asians exhibit differential catalytic activities for seven CYP3A4 substrate drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Defective activity of recombinant cytochromes P450 3A4.2 and 3A4.16 in oxidation of midazolam, nifedipine, and testosterone

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

CYP3A activity in African American and European American men: population differences and functional effect of the CYP3A4*1B5'-promoter region polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

The P450 oxidoreductase genotype is associated with CYP3A activity in vivo as measured by the midazolam phenotyping test

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Efavirenz induces CYP2B6-mediated hydroxylation of bupropion in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Relationship between response to risperidone, plasma concentrations of risperidone and CYP3A4 polymorphisms in schizophrenia patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Novel CYP3A4 intron 6 single nucleotide polymorphism is associated with simvastatin-mediated cholesterol reduction in the Rotterdam Study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

CYP3A4*1G polymorphism is associated with lipid-lowering efficacy of atorvastatin but not of simvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Genetic polymorphisms in CYP3A4 are associated with withdrawal symptoms and adverse reactions in methadone maintenance patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

CYP3A4*1G genetic polymorphism influences CYP3A activity and response to fentanyl in Chinese gynecologic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Association between HTR2C gene polymorphisms and the metabolic syndrome in patients using antipsychotics: a replication study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Association between HTR2C polymorphisms and metabolic syndrome in patients with schizophrenia treated with atypical antipsychotics.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Association between LEP and LEPR gene polymorphisms and dyslipidemia in patients using atypical antipsychotic medication

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Association between HTR2C and HTR2A polymorphisms and metabolic abnormalities in patients treated with olanzapine or clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Association study of MDR1 and 5-HT2C genetic polymorphisms and antipsychotic-induced metabolic disturbances in female patients with schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

HTR2C gene polymorphisms and the metabolic syndrome in patients with schizophrenia: a replication study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

The association between HTR2C gene polymorphisms and the metabolic syndrome in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Influence of 5-HT2C receptor and leptin gene polymorphisms, smoking and drug treatment on metabolic disturbances in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Weight gain associated with the -759C/T polymorphism of the 5HT2C receptor and olanzapine

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Olanzapine-induced weight gain is associated with the -759C/T and -697G/C polymorphisms of the HTR2C gene.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Clozapine-induced weight gain associated with the 5HT2C receptor -759C/T polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Association of HTR2C, but not LEP or INSIG2, genes with antipsychotic-induced weight gain in a German sample.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

-759 C/T polymorphism of 5-HT2C receptor gene and early phase weight gain associated with antipsychotic drug treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Polymorphisms of the HTR2C gene and antipsychotic-induced weight gain: an update and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Polymorphisms of the 5-HT2C receptor and leptin genes are associated with antipsychotic drug-induced weight gain in Caucasian subjects with a first-episode psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Genetic Polymorphisms in the HTR2C and Peroxisome Proliferator-Activated Receptors Are Not Associated with Metabolic Syndrome in Patients with Schizophrenia Taking Clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Lack of association between the -759C/T polymorphism of the 5-HT2C receptor gene and olanzapine-induced weight gain among Korean schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

DRD4 48 bp VNTR but not 5-HT 2C Cys23Ser receptor polymorphism is related to antipsychotic-induced weight gain

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Antidepressive-drug-induced bodyweight gain is associated with polymorphisms in genes coding for COMT and TPH1.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Lack of association between the -759C/T polymorphism of the 5-HT2C receptor gene and clozapine-induced weight gain among German schizophrenic individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

HTR2C haplotypes and antipsychotics-induced weight gain: X-linked multimarker analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Absence of weight gain association with the HTR2C -759C/T polymorphism in patients with schizophrenia treated with iloperidone

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Pharmacogenetic testing to predict antipsychotic-induced weight gain: a systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

HTR2A A-1438G/T102C polymorphisms predict negative symptoms performance upon aripiprazole treatment in schizophrenic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Serotonin receptor 2A gene polymorphism (-1438A/G) and short-term treatment response to citalopram

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Effects of the serotonin type 2A, 3A and 3B receptor and the serotonin transporter genes on paroxetine and fluvoxamine efficacy and adverse drug reactions in depressed Japanese patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

5-HT2A gene variants influence specific and different aspects of antidepressant response in Japanese and Italian mood disorder patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Response to fluoxetine and serotonin 1A receptor (C-1019G) polymorphism in Taiwan Chinese major depressive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Variants of dopamine and serotonin candidate genes as predictors of response to risperidone treatment in first-episode schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Effect of serotonin receptor 2A gene polymorphism on mirtazapine response in major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Interaction of serotonin-related genes affects short-term antidepressant response in major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

No evidence for interaction between 5-HT2A receptor and serotonin transporter genes in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Investigation of serotonin-related genes in antidepressant response

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Polymorphisms in the SLC6A4 and HTR2A genes influence treatment outcome following antidepressant therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Polymorphisms in GRIK4, HTR2A, and FKBP5 show interactive effects in predicting remission to antidepressant treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Pharmacogenetic analysis of the mGlu2/3 agonist LY2140023 monohydrate in the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

HTR2A gene variation is involved in antidepressant treatment response

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

No association between lithium full responders and the DRD1, DRD2, DRD3, DAT1, 5-HTTLPR and HTR2A genes in a Sardinian sample

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

5HT1A and 5HT2A receptor genes in treatment response phenotypes in major depressive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Variation in catechol-O-methyltransferase is associated with duloxetine response in a clinical trial for major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Resequencing of serotonin-related genes and association of tagging SNPs to citalopram response

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Genetic predictors of response to antidepressants in the GENDEP project

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

HTR2A is associated with SSRI response in major depressive disorder in a Japanese cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

CGS 10746B: an atypical antipsychotic candidate that selectively decreases dopamine release at behaviorally effective doses.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Tardive dyskinesia and DRD3, HTR2A and HTR2C gene polymorphisms in Russian psychiatric inpatients from Siberia.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Pharmacogenetics of parkinsonism, rigidity, rest tremor, and bradykinesia in African-Caribbean inpatients: differences in association with dopamine and serotonin receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

The role of dopamine D3, 5-HT2A and 5-HT2C receptor variants as pharmacogenetic determinants in tardive dyskinesia in African-Caribbean patients under chronic antipsychotic treatment: Curacao extrapyramidal syndromes study IX.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Novel 5-HTTLPR allele associates with higher serotonin transporter binding in putamen: a [(11)C] DASB positron emission tomography study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Norepinephrine and serotonin transporter genes: impact on treatment response in depression

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Association study of olanzapine-induced weight gain and therapeutic response with SERT gene polymorphisms in female schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Association study of paroxetine therapeutic response with SERT gene polymorphisms in patients with major depressive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Acute antipyschotic efficacy and side effects in schizophrenia: association with serotonin transporter promoter genotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

The serotonin transporter polymorphism, 5HTTLPR, is associated with a faster response time to sertraline in an elderly population with major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

5-HTTLPR modulates antidepressant efficacy in depressed women.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Moderation of antidepressant response by the serotonin transporter gene.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Is 5-HTTLPR linked to the response of selective serotonin reuptake inhibitors in MDD?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Controlled clinical comparison of paroxetine and fluvoxamine considering the serotonin transporter promoter polymorphism.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Interaction between serotonin transporter gene variants and life events predicts response to antidepressants in the GENDEP project.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Influence of serotonin transporter gene polymorphisms on clozapine response in Brazilian schizophrenics

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Catechol-O-methyltransferase Val158Met polymorphism affects therapeutic response to mood stabilizer in symptomatic manic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Serotonin transporter promoter gene polymorphism and long-term outcome of antidepressant treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Relation of serotonin transporter genetic variation to efficacy of escitalopram for generalized anxiety disorder in older adults

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Monoamine transporter gene polymorphisms affect susceptibility to depression and predict antidepressant response.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Serotonin transporter polymorphism as a predictor for escitalopram treatment of major depressive disorder comorbid with alcohol dependence.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Effects of the serotonin transporter gene promoter polymorphism on mirtazapine and paroxetine efficacy and adverse events in geriatric major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Antipanic efficacy of paroxetine and polymorphism within the promoter of the serotonin transporter gene

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Response to lithium prophylaxis: interaction between serotonin transporter and BDNF genes.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Further evidence of a combined effect of SERTPR and TPH on SSRIs response in mood disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Serotonin transporter gene promoter polymorphism predicts SSRI response in generalized social anxiety disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Response of risperidone treatment may be associated with polymorphisms of HTT gene in Chinese schizophrenia patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Serotonin transporter gene polymorphisms and sertraline response in major depression patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

The role of clinical variables, neuropsychological performance and SLC6A4 and COMT gene polymorphisms on the prediction of early response to fluoxetine in major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

A 40-basepair VNTR polymorphism in the dopamine transporter (DAT1) gene and the rapid response to antidepressant treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Analysis of association between the serotonin transporter and antidepressant response in a large clinical sample

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

No association of serotonin transporter polymorphism (5-HTTVNTR and 5-HTTLPR) with characteristics and treatment response to atypical antipsychotic agents in schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Polymorphism of the 5-HT transporter and response to antidepressants: randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Haplotype analysis confirms association of the serotonin transporter (5-HTT) gene with schizophrenia in the Han Chinese population.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Serotonin transporter promoter region polymorphisms do not influence treatment response to escitalopram in patients with major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Serotonin transporter linked promoter (polymorphism) in the serotonin transporter gene may be associated with antidepressant-induced mania in bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Association study of the INPP1, 5HTT, BDNF, AP-2beta and GSK-3beta GENE variants and restrospectively scored response to lithium prophylaxis in bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Interaction analysis between 5-HTTLPR and TNFA -238/-308 polymorphisms in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Failure to replicate genetic associations with antidepressant treatment response in duloxetine-treated patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Genetic polymorphisms in the treatment of depression: speculations from an augmentation study using atomoxetine.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Further evidence for a possible association between serotonin transporter gene and lithium prophylaxis in mood disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Serotonin transporter polymorphisms and early response to antipsychotic treatment in first episode of psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Early response to selective serotonin reuptake inhibitors in panic disorder is associated with a functional 5-HT1A receptor gene polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Rapid response to paroxetine is associated with plasma paroxetine levels at 4 but not 8 weeks of treatment, and is independent of serotonin transporter promoter polymorphism in Japanese depressed patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Genetic and pharmacokinetic factors affecting the initial pharmacotherapeutic effect of paroxetine in Japanese patients with panic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Serotonin transporter gene and response to lithium augmentation in depression

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Predictive factors for responding to sertraline treatment: views from plasma catecholamine metabolites and serotonin transporter polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Sequence analysis of the serotonin transporter and associations with antidepressant response

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Serotonin transporter gene promoter polymorphisms modify the association between paroxetine serotonin transporter occupancy and clinical response in major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

The role of 5-HTTLPR polymorphism in antidepressant-associated mania in bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Association between a functional serotonin transporter promoter polymorphism and citalopram treatment in adult outpatients with major depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Serotonin transporter gene polymorphism associated with short-term treatment response to venlafaxine

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Serotonin transporter polymorphisms and the occurrence of adverse events during treatment with selective serotonin reuptake inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Polymorphism of human cytochrome P450 enzymes and its clinical impact

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Utility of integrated pharmacogenomic testing to support the treatment of major depressive disorder in a psychiatric outpatient setting

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Effect of Cytochrome P450 Enzyme Polymorphisms on Pharmacokinetics of Venlafaxine

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Effect of a new functionalCYP3A4polymorphism on calcineurin inhibitors’ dose requirements and trough blood levels in stable renal transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Association of CYP3A4*18B polymorphisms with the pharmacokinetics of cyclosporine in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

The association between HTR2C polymorphisms and obesity in psychiatric patients using antipsychotics: a cross-sectional study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Intuitive pharmacogenetics: spontaneous risperidone dosage is related to CYP2D6, CYP3A5 and ABCB1 genotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

Cytochrome P450 CYP1A2, CYP2C9, CYP2C19 and CYP2D6 genes are not associated with response and remission in a sample of depressive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

CYP2D6*3, *4, *5 AND *6 POLYMORPHISMS AND ANTIPSYCHOTIC-INDUCED EXTRAPYRAMIDAL SIDE-EFFECTS IN PATIENTS RECEIVING ANTIPSYCHOTIC THERAPY

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

ABCB1 and cytochrome P450 genotypes and phenotypes: Influence on methadone plasma levels and response to treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2013.825579

10.3109/09540261.2013.825579

21 January 2018

Identifiers

DOI

1 reference

29 August 2017

1 reference